Session Synopsis: Health care systems that are implementing precision medicine programs face practical challenges: empowering physicians with genomic education; meaningful interpretation of molecular Dx test results; and patient access to drugs including through clinical trials. Three precision medicine leaders from large hospitals systems will discuss how they are addressing these challenges in this expert panel.
Session Chair Profile
CEO and Chairperson, N-of-One
Christine Cournoyer is Chief Executive Officer of N-of-One. Prior to joining N-of-One, she was President and Chief Operating Officer of Picis, a leading company in the healthcare IT market. Picis provided software solutions that bridge revenue cycle and clinical workflow management for high-acuity operations within hospitals, including emergency rooms, operating rooms, and critical care. Picis’ systems were installed in more than 1,800 medical centers, hospitals, and integrated delivery networks in 19 countries around the world. Ms. Cournoyer served as President and Chief Operating Officer of Lightbridge, Inc. and held senior management positions at IBM, including Vice President of Business Transformation as well as Chief Information Officer of IBM’s software group. She also served as Senior Vice President at Lotus Development. Ms. Cournoyer was named one of the “10 Most Influential Women in Technology” by Businessweek. She is currently a Corporator for Emerson Hospital and a member of both the Boston Club and the Women Corporate Directors.
M.D., FACP, CEO and Executive Director, Inova Schar Cancer Institute
Dr. Trump joined the Inova Schar Cancer Institute (ISCI) as its Chief Executive Officer on January 5, 2015. He most recently served as president and CEO of Roswell Park Cancer Institute (RPCI) in Buffalo, NY. Roswell Park Cancer Institute is one of the nation’s nationally designated cancer centers. Under Trump’s 13-year leadership, Roswell Park substantially expanded its patient care, research and education programs. Dr. Trump is a medical oncologist who specializes in the treatment of patients with genitourinary cancers, especially prostate and bladder cancer. He has received peer reviewed research funding from the National Cancer Institute, the Department of Defense and the American Cancer Society. Since his assuming the position of CEO, ISCI in 2015, he has recruited more the 30 cancer clinicians and scientists to develop ISCI program in drug discovery, biomarker development, clinical genomics and clinical cancer trials. ISCI established the first Molecular Tumor Board in the Spring of 2016.
M.D., MBA, Executive Director, Swedish Cancer Institute
Thomas Brown, MD, MBA is Executive Director of Swedish Cancer Institute, and Co-Chair of the Cancer Leadership Council for Providence Health & Services. He served as COO of the University of Arizona Cancer Center, and on the faculty at MD Anderson Cancer Center and Duke University. He graduated from Johns Hopkins University, with an MBA from Rice University, and a medical degree from the Medical College of Virginia; completing a medical oncology fellowship at Johns Hopkins University. His research has focused on developmental therapeutics. Dr. Brown serves on numerous boards, to include: P4 Medicine Institute; and the American Cancer Society.